Eczematous Vesicular Rruption and Exacerbation of Chronic Spontaneous Urticaria Associated with Secukinumab
- Author:
Sang-Min CHOI
1
;
Bark-Lynn LEW
;
Woo-Young SIM
;
Soon-Hyo KWON
Author Information
1. Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea
- Publication Type:Case Report
- From:Korean Journal of Dermatology
2022;60(9):611-614
- CountryRepublic of Korea
- Language:English
-
Abstract:
The pathogenesis of chronic spontaneous urticaria (CSU) is complex. Though the involvement of functional autoantibodies and imbalance of T helper (Th) cell subsets have been reported, the exact mechanism remains elusive.We report a case of eczematous vesicular eruption and exacerbation of CSU in a patient with psoriasis after treatment with secukinumab, an anti-interleukin (IL)-17 monoclonal antibody. The eczematoid eruption subsided after the administration of systemic steroids, but the exacerbation of CSU was not controlled. After switching the therapy to guselkumab, an anti-IL-23 monoclonal antibody, to supplement the control of the psoriasis lesions, the patient’s urticaria flare-ups were well controlled with only H1 antihistamines. We hypothesize that the Th2-skewed immune response induced by anti-IL-17 treatment in predisposed patients might have resulted in the eczematous eruption and exacerbation of CSU.
